OC
MCID: OVR042
MIFTS: 83

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 58 12 77 54 26 76 38 30 56 6 44 3 15
Ovarian Carcinoma 54 26 13 56 17 74
Ovarian Neoplasms 56 6 45
Ovarian Neoplasm 12 17 74
Epithelial Ovarian Cancer 76 74
Neoplasm of Ovary 30 6
Primary Malignant Neoplasm of Ovary 74
Malignant Neoplasm of the Ovary 26
Malignant Tumor of the Ovary 26
Malignant Neoplasm of Ovary 74
Malignant Tumour of Ovary 12
Ovarian Cancer, Somatic 58
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 26
Tumor of the Ovary 12
Cancer, Ovarian 41
Ovary Neoplasm 12
Oc 76

Characteristics:

OMIM:

58
Inheritance:
somatic mutation


HPO:

33
ovarian cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:2394
OMIM 58 167000
KEGG 38 H00027
ICD9CM 36 183.0
MeSH 45 D010051
NCIt 51 C4984 C7431
SNOMED-CT 69 93934004
ICD10 34 C56
SNOMED-CT via HPO 70 254838004 263681008 60718004

Summaries for Ovarian Cancer

NIH Rare Diseases : 54 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and ovarian cancer 1, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are MicroRNAs in cancer and TGF-Beta Pathway. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include ovary, testes and t cells, and related phenotypes are abnormality of metabolism/homeostasis and breast carcinoma

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Genetics Home Reference : 26 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

OMIM : 58 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

MedlinePlus : 44 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

Novus Biologicals : 57 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 76 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 77 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 737)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 35.4 BRCA1 BRCA2 BRIP1 PALB2 PTEN
2 ovarian cancer 1 35.2 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
3 breast cancer 34.4 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
4 hereditary site-specific ovarian cancer syndrome 34.3 BRCA1 BRCA2
5 pancreatic cancer 34.1 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
6 lynch syndrome 33.6 BRAF BRCA1 BRCA2 CTNNB1 KRAS
7 ovarian clear cell carcinoma 33.5 KRAS PIK3CA PTEN
8 ovary epithelial cancer 33.1 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
9 ovarian disease 32.8 AKT1 BRCA1 BRCA2 PTEN
10 colorectal cancer 32.4 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
11 endometrial cancer 32.3 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
12 adenocarcinoma 32.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
13 prostate cancer 32.1 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
14 lung cancer 32.0 AKT1 BRAF CDH1 ERBB2 KRAS MIR200A
15 cervical cancer 31.7 AKT1 CDH1 CTNNB1 ERBB2 MIR214 PIK3CA
16 fallopian tube carcinoma 31.6 BRCA1 BRCA2 ERBB2
17 primary peritoneal carcinoma 31.6 BRCA1 BRCA2 ERBB2
18 lung cancer susceptibility 3 31.4 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
19 endometrial adenocarcinoma 31.4 AKT1 CTNNB1 ERBB2 KRAS PTEN
20 melanoma 31.4 BRAF MIR200A MIR200B MIR200C PTEN
21 medulloblastoma 31.4 AKT1 BRCA2 CTNNB1 ERBB2 PIK3CA PTEN
22 glioblastoma 31.4 AKT1 BRAF BRCA2 ERBB2 PIK3CA PTEN
23 squamous cell carcinoma 31.4 AKT1 BRAF CDH1 CTNNB1 ERBB2 PIK3CA
24 pancreas adenocarcinoma 31.3 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
25 cholangiocarcinoma 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
26 gastrointestinal stromal tumor 31.2 AKT1 BRAF KRAS PTEN
27 bladder urothelial carcinoma 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
28 squamous cell carcinoma, head and neck 31.2 AKT1 BRAF CDH1 CTNNB1 ERBB2 MIR200A
29 carcinosarcoma 31.2 CTNNB1 ERBB2 KRAS PIK3CA PTEN
30 transitional cell carcinoma 31.2 BRAF CDH1 ERBB2 PTEN
31 adrenocortical carcinoma, hereditary 31.1 BRAF CTNNB1 MIR214 PIK3CA
32 fanconi anemia, complementation group j 31.1 BRCA1 BRIP1 PALB2
33 fanconi anemia, complementation group a 31.1 BRCA1 BRCA2 BRIP1 PALB2
34 hepatocellular carcinoma 31.1 AKT1 CDH1 CTNNB1 KRAS MIR200A MIR200B
35 in situ carcinoma 31.1 BRCA1 CDH1 ERBB2
36 thyroid cancer 31.1 AKT1 BRAF CDH1 CTNNB1 KRAS PIK3CA
37 esophageal cancer 31.1 AKT1 CDH1 CTNNB1 ERBB2 KRAS PIK3CA
38 papillary carcinoma 31.1 BRAF CDH1 ERBB2
39 cystadenocarcinoma 31.0 AKT1 ERBB2 PIK3CA
40 bilateral breast cancer 31.0 BRCA1 BRCA2 ERBB2 PALB2
41 ductal carcinoma in situ 31.0 AKT1 BRCA1 BRCA2 CDH1 ERBB2
42 glioblastoma multiforme 31.0 AKT1 ERBB2 PIK3CA PTEN
43 gallbladder cancer 31.0 AKT1 CDH1 ERBB2 KRAS PIK3CA
44 breast adenocarcinoma 30.9 AKT1 ERBB2 KRAS PIK3CA PTEN
45 li-fraumeni syndrome 30.9 BRCA1 BRCA2 PTEN
46 glioma 30.9 BRAF BRCA2 ERBB2 PIK3CA PTEN
47 sporadic breast cancer 30.9 BRCA1 BRCA2 ERBB2 PTEN
48 peutz-jeghers syndrome 30.9 BRCA2 CTNNB1 PTEN
49 ovarian serous cystadenocarcinoma 30.9 AKT1 BRAF ERBB2 PIK3CA
50 serous cystadenocarcinoma 30.8 AKT1 ERBB2 PIK3CA

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Human phenotypes related to Ovarian Cancer:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 breast carcinoma 33 HP:0003002
3 dysgerminoma 33 HP:0100621
4 ovarian papillary adenocarcinoma 33 HP:0006774

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
dysgerminoma
ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM:

167000

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

27 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.5 CTNNB1 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.5 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.5 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.5 PIK3CA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.5 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.5 BRAF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.5 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.5 AKT1 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.5 BRAF PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.5 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.5 AKT1 BRAF CTNNB1 KRAS PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.5 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.5 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.5 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.5 CTNNB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.5 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.5 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.5 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.5 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.5 AKT1 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.5 BRAF CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.5 CTNNB1 KRAS PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.5 AKT1 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.5 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.5 CTNNB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.5 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.5 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.5 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.5 AKT1 CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.5 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.5 KRAS
32 Decreased viability GR00055-A-2 10.35 BRAF KRAS
33 Decreased viability GR00106-A-0 10.35 KRAS
34 Decreased viability GR00221-A-1 10.35 CDH1 KRAS
35 Decreased viability GR00221-A-2 10.35 BRCA1 KRAS
36 Decreased viability GR00221-A-3 10.35 BRCA1
37 Decreased viability GR00221-A-4 10.35 BRAF
38 Decreased viability GR00301-A 10.35 BRAF BRCA1 CDH1 KRAS
39 Decreased viability GR00381-A-1 10.35 BRAF KRAS
40 Decreased viability GR00402-S-2 10.35 BRAF BRCA1 CDH1 KRAS
41 Decreased cell migration GR00055-A-1 9.8 AKT1 BRAF CTNNB1 KRAS PIK3CA
42 Increased cell migration GR00055-A-3 9.56 BRAF CTNNB1 KRAS PIK3CA
43 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 AKT1 BRCA1 BRCA2 PALB2 PRKN PTEN
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 AKT1 BRAF BRCA1 BRCA2 BRIP1 PALB2
46 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
2 cardiovascular system MP:0005385 10.35 AKT1 BRAF BRCA1 CDH1 CTNNB1 ERBB2
3 behavior/neurological MP:0005386 10.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2
4 growth/size/body region MP:0005378 10.32 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
5 embryo MP:0005380 10.28 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
6 homeostasis/metabolism MP:0005376 10.27 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
7 endocrine/exocrine gland MP:0005379 10.26 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
8 integument MP:0010771 10.26 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
9 neoplasm MP:0002006 10.22 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
10 digestive/alimentary MP:0005381 10.15 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
11 nervous system MP:0003631 10.15 AKT1 BRAF BRCA1 BRCA2 BRIP1 CTNNB1
12 muscle MP:0005369 10.09 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
13 limbs/digits/tail MP:0005371 10.06 BRAF BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
14 normal MP:0002873 10.02 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
15 reproductive system MP:0005389 9.9 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
16 pigmentation MP:0001186 9.65 BRAF BRCA1 CTNNB1 KRAS PTEN
17 respiratory system MP:0005388 9.56 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
18 skeleton MP:0005390 9.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show top 50) (show all 228)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Abstral 19 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 19 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 19 50 EVEROLIMUS Novartis March 2009
6
Akynzeo 19 50 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 19 50 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 19 50 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anexsia 19 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
10
Anzemet 19 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
11
Aredia 19 50 PAMIDRONATE DISODIUM Chiron August 1996
12
Arimidex 19 50 ANASTROZOLE AstraZeneca January 1996
13
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
14
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
15
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
16
Avastin 19 50 BEVACIZUMAB Genentech July 2009
17
Beleodaq 19 50 BELINOSTAT Spectrum Pharmaceuticals July 2014
18
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
19
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
20
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
21
Bromfenac 19 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
22
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
23
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
24
CEA-Scan 19 Immunomedics April 1996
25
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
26
Clolar 19 50 CLOFARABINE Genzyme December, 2004
27
Cometriq 19 50 CABOZANTINIB S-MALATE Exelixis November 2012
28
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
29
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
30
Doxil 19 50 DOXORUBICIN HYDROCHLORIDE Alza June 1999
31
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
32
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
33
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
34
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
35
Emend 19 50 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
36
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
37
Erivedge 19 50 VISMODEGIB Genentech January 2012
38
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
39
Ethyol 19 AMIFOSTINE Alza December 8, 1995
40
Eulexin 19 FLUTAMIDE Schering-Plough June 1996
41
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
42
Farydak 19 50 PANOBINOSTAT LACTATE Novartis February 2015
43
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
44
Femara 19 50 LETROZOLE Novartis January 2001
45
Feridex I.V. 19 FERUMOXIDES Advanced Magnetics February 1996
46
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
47
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
48
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
49
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
50
Gemzar 19 50 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 716)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Peppermint Approved Phase 4
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Ferrous fumarate Approved Phase 4,Early Phase 1,Not Applicable 141-01-5
9
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 114977-28-5 148124
10
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
11
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
12
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
15
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
16
Iron Approved, Experimental Phase 4,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
17
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 54670067 5785
18
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-18-4 6057
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Coagulants Phase 4,Phase 2,Phase 1,Not Applicable
28 Hemostatics Phase 4,Phase 2,Phase 1,Not Applicable
29 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2590)
# Name Status NCT ID Phase Drugs
1 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
4 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
5 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
6 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
7 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
8 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
9 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
10 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
12 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
13 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
14 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
15 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
16 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
17 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
18 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
20 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
21 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
22 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
23 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
24 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
26 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
27 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
28 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
29 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
30 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
31 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
32 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
33 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
34 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
35 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
36 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
37 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
38 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
39 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
40 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
41 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
42 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
43 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
44 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
45 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
46 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
47 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed NCT02421588 Phase 3 Lurbinectedin (PM01183);Pegylated liposomal doxorubicin (PLD);Topotecan
48 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
49 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone
50 Women's Activity and Lifestyle Study in Connecticut Completed NCT02107066 Phase 3

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 30 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 30

Anatomical Context for Ovarian Cancer

MalaCards organs/tissues related to Ovarian Cancer:

42
Ovary, Testes, T Cells, Endothelial, Breast, Lymph Node, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

20
The Ovary

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 16356)
# Title Authors Year
1
Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. ( 30766885 )
2019
2
Epithelioid glioblastoma presenting as aphasia in a young adult with ovarian cancer: A case report. ( 30997093 )
2019
3
Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. ( 31036035 )
2019
4
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. ( 30964716 )
2019
5
Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand. ( 30789886 )
2019
6
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. ( 30725383 )
2019
7
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations. ( 29790947 )
2019
8
Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). ( 30616086 )
2019
9
Effectiveness of advanced nursing care on depression in patients with ovarian cancer: A protocol of systematic review of randomized controlled trial. ( 31027100 )
2019
10
Identification of Key Candidate Genes and Pathways for Relationship between Ovarian Cancer and Diabetes Mellitus Using Bioinformatical Analysis ( 30678426 )
2019
11
Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer. ( 31074246 )
2019
12
Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics. ( 30913953 )
2019
13
Evaluation of ovarian cancer risk in granulosa cells treated with steroid-depleted endometriosis serum: Role of NF-κB/RelA and AKT. ( 30515820 )
2019
14
Palmar Fasciitis and Polyarthritis Syndrome Associated With Ovarian Cancer: A Case Report. ( 31058664 )
2019
15
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma. ( 31104212 )
2019
16
Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles. ( 31055798 )
2019
17
LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α). ( 30912527 )
2019
18
Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. ( 30536571 )
2019
19
Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. ( 30272587 )
2019
20
Hydropic leiomyoma presenting as a rare condition of pseudo-Meigs syndrome: literature review and a case of a pseudo-Meigs syndrome mimicking ovarian carcinoma with elevated CA125. ( 30635302 )
2019
21
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. ( 30305729 )
2019
22
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations. ( 30414230 )
2019
23
A rare case of linitis plastica of the colon from ovarian carcinoma. ( 30949339 )
2019
24
Systemic Lupus Erythematosus Associated with Ovarian Cancer. ( 30333422 )
2019
25
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer. ( 31056861 )
2019
26
Co-occurrence of Mayer-Rokitansky-Küster-Hauser syndrome and ovarian cancer: A case report and review of the literature. ( 30957000 )
2019
27
Clinical significance of melanoma cell adhesion molecule CD146 and VEGFA expression in epithelial ovarian cancer. ( 30675307 )
2019
28
Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer. ( 30790382 )
2019
29
miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism. ( 31101765 )
2019
30
EPIDEMIOLOGY AND MANAGEMENT OF OVARIAN CANCER BASED ON THE CLINICAL EXPERIENCE OF THE SOUTHERN REGION OF UKRAINE. ( 31101771 )
2019
31
Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants. ( 31103675 )
2019
32
Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. ( 31103743 )
2019
33
Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer. ( 31104207 )
2019
34
DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p. ( 31104928 )
2019
35
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. ( 31105696 )
2019
36
Long noncoding RNA TP73-AS1 accelerates the epithelial ovarian cancer via epigenetically repressing p21. ( 31105851 )
2019
37
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. ( 31105878 )
2019
38
Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. ( 31107721 )
2019
39
Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis. ( 31108164 )
2019
40
Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation. ( 31108893 )
2019
41
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". ( 31109041 )
2019
42
Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer. ( 31110157 )
2019
43
Senescence-related deterioration of intercellular junctions in the peritoneal mesothelium promotes the transmesothelial invasion of ovarian cancer cells. ( 31110245 )
2019
44
Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer. ( 31110965 )
2019
45
Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin. ( 31061066 )
2019
46
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. ( 31061096 )
2019
47
Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process. ( 31061661 )
2019
48
M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. ( 31062668 )
2019
49
Tripartite Motif-Containing Protein 59 (TRIM59) Promotes Epithelial Ovarian Cancer Progression via the Focal Adhesion Kinase(FAK)/AKT/Matrix Metalloproteinase (MMP) Pathway. ( 31062766 )
2019
50
Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment. ( 31064389 )
2019

Variations for Ovarian Cancer

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

76
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691

ClinVar genetic disease variations for Ovarian Cancer:

6 (show top 50) (show all 611)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRIP1 NM_032043.2(BRIP1): c.139C> G (p.Pro47Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs28903098 GRCh37 Chromosome 17, 59937223: 59937223
2 BRIP1 NM_032043.2(BRIP1): c.139C> G (p.Pro47Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs28903098 GRCh38 Chromosome 17, 61859862: 61859862
3 BRIP1 NM_032043.2(BRIP1): c.2392C> T (p.Arg798Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs137852986 GRCh37 Chromosome 17, 59793412: 59793412
4 BRIP1 NM_032043.2(BRIP1): c.2392C> T (p.Arg798Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs137852986 GRCh38 Chromosome 17, 61716051: 61716051
5 PRKN PARK2, DEL deletion Pathogenic
6 PRKN NM_004562.2(PRKN): c.823C> T (p.Arg275Trp) single nucleotide variant Pathogenic rs34424986 GRCh37 Chromosome 6, 162206852: 162206852
7 PRKN NM_004562.2(PRKN): c.823C> T (p.Arg275Trp) single nucleotide variant Pathogenic rs34424986 GRCh38 Chromosome 6, 161785820: 161785820
8 PRKN NM_004562.2(PRKN): c.719C> T (p.Thr240Met) single nucleotide variant Conflicting interpretations of pathogenicity rs137853054 GRCh37 Chromosome 6, 162394349: 162394349
9 PRKN NM_004562.2(PRKN): c.719C> T (p.Thr240Met) single nucleotide variant Conflicting interpretations of pathogenicity rs137853054 GRCh38 Chromosome 6, 161973317: 161973317
10 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
11 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
12 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
13 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
14 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh37 Chromosome 11, 132527098: 132527098
15 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh38 Chromosome 11, 132657203: 132657203
16 RRAS2 NM_012250.6(RRAS2): c.215A> T (p.Gln72Leu) single nucleotide variant Pathogenic rs113954997 GRCh37 Chromosome 11, 14316390: 14316390
17 RRAS2 NM_012250.6(RRAS2): c.215A> T (p.Gln72Leu) single nucleotide variant Pathogenic rs113954997 GRCh38 Chromosome 11, 14294844: 14294844
18 CDH1 NM_004360.5(CDH1): c.2512A> G (p.Ser838Gly) single nucleotide variant Uncertain significance rs121964872 GRCh37 Chromosome 16, 68867265: 68867265
19 CDH1 NM_004360.5(CDH1): c.2512A> G (p.Ser838Gly) single nucleotide variant Uncertain significance rs121964872 GRCh38 Chromosome 16, 68833362: 68833362
20 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
21 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
22 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
23 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
24 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
25 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
26 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
27 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
28 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
29 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
30 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
31 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
32 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
33 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
35 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
38 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
40 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
42 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
43 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
44 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh38 Chromosome 17, 39725125: 39725125
45 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
46 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
47 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
48 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
49 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
50 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551

Copy number variations for Ovarian Cancer from CNVD:

7 (show top 50) (show all 8010)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion C1orf70 Ovarian cancer
42 13454 1 1 23549970 Deletion C1orf86 Ovarian cancer
43 13455 1 1 23549970 Deletion C1orf89 Ovarian cancer
44 13456 1 1 23549970 Deletion C1orf93 Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion